Cabaletta Bio Inc Ordinary Shares CABA
News
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs
Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis